Skip to main content
$1.30 -0.01 (-0.76%) At close · Aug 5
Market Cap
$423.15M
Shares
338.52M

Ocugen, Inc. Earnings Call Transcripts

Every quarterly earnings call for Ocugen, Inc. (OCGN) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Conference
Investor event
2026-06-04
Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Ocugen, Inc. Q1 FY2026 Earnings Call
Confident tone OCU400 for retinitis pigmentosa (RP) Clinical milestones and timeline catalysts OCU410ST for Stargardt disease
Revenue
$1.53M
▲ 3.5% YoY
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Ocugen, Inc. Q4 FY2025 Earnings Call
Confident tone OCU410 (GA) Phase 2 data and Phase 3 initiation Rolling BLA submission for OCU400 in 2026 OCU400 Phase 3 Limelight trial enrollment complete
Revenue
$*
▼ 125.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Ocugen, Inc. Q3 FY2025 Earnings Call
Confident tone OCU400 Phase 3 retinitis pigmentosa Clinical trial enrollment and timelines OCU410 geographic atrophy / dry AMD
Revenue
$1.75M
▲ 54.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-01
Ocugen, Inc. Q2 FY2025 Earnings Call
Revenue
$1.37M
▲ 20.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Ocugen, Inc. Q1 FY2025 Earnings Call
Confident tone OCU410 dry AMD / geographic atrophy OCU400 RP gene therapy program Regulatory alignment with FDA and EMA
Revenue
$1.48M
▲ 46.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-05
Ocugen, Inc. Q4 FY2024 Earnings Call
Confident tone OCU410 Dry AMD / Geographic Atrophy OCU410ST Stargardt Disease OCU400 Retinitis Pigmentosa Phase 3
Revenue
$764,000*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-08
Ocugen, Inc. Q3 FY2024 Earnings Call
Confident tone OCU410 for Geographic Atrophy (ArMaDa Trial) OCU410ST for Stargardt Disease (GARDian Trial) OCU400 Phase 3 liMeliGhT Clinical Trial for RP
Revenue
$1.14M
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Ocugen, Inc. Q2 FY2024 Earnings Call
Confident tone OCU400 Phase 3 RP program OCU410 geographic atrophy / dry AMD Expanded Access Program for RP
Revenue
$1.14M
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Ocugen, Inc. Q1 FY2024 Earnings Call
Confident tone OCU400 Phase III liMeliGhT trial for RP/LCA OCU410/Ocu410ST for dry AMD and Stargardt Cell therapy platform and NeoCart
Revenue
$1.01M
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q3
2023-11-09
Ocugen, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-22
Ocugen, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-05
Ocugen, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Ocugen, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Ocugen, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-0.10
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-05
Ocugen, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-06
Ocugen, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-25
Ocugen, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Ocugen, Inc. Q3 FY2021 Earnings Call
Revenue
$
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-06
Ocugen, Inc. Q2 FY2021 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-07
Ocugen, Inc. Q1 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-18
Ocugen, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q2
2020-08-14
Ocugen, Inc. Q2 FY2020 Earnings Call
Revenue
$42,620
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-27
Ocugen, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–24 of 24 earnings calls
Key facts CIK 1372299 CUSIP 67577C105 13F (30d) 34 filings 34 filers Visit website Investor relations